Search

Women’s genitalia are constructed as a bodily site requiring ongoing surveillance, maintenance and modification to conform to social norms. Women engage in a range of genital health, hygiene and beauty practices, including the use of commercial and homemade vaginal douches, washes, wipes, sprays and pubic hair removal, to modify their bodies. Using a social constructionist framework, we draw on interviews with 49 Canadian women to examine the construction of idealized (Western) genitalia as hairless, odourless and free of discharge, and “natural” female genitalia as problematic through the mobilization of normative femininity and (hetero)sexuality discourses. Theorizing women’s genital health, hygiene and beauty practices as a form of body work, we examine how women’s genital body work is constructed as a necessary and thus normative practice of femininity undertaken in the pursuit of idealized genitalia. A minority perspective that drew on alternative discourses to construct female genitalia as acceptable irrespective of genital body work is examined. Throughout our analysis, we examine the ways in which women negotiate issues of agency and choice in relation to their genital body work. Implications for women’s health in the context of the vaginal microbiome are explored. [ABSTRACT FROM AUTHOR]

Background: Biobanks are considered to be key infrastructures for research development and have generated a lot of debate about their ethical, legal and social implications (ELSI). While the focus has been on human genomic research, rapid advances in human microbiome research further complicate the debate.Discussion: We draw on two cystic fibrosis biobanks in Toronto, Canada, to illustrate our points. The biobanks have been established to facilitate sample and data sharing for research into the link between disease progression and microbial dynamics in the lungs of pediatric and adult patients. We begin by providing an overview of some of the ELSI associated with human microbiome research, particularly on the implications for the broader society. We then discuss ethical considerations regarding the identifiability of samples biobanked for human microbiome research, and examine the issue of return of results and incidental findings. We argue that, for the purposes of research ethics oversight, human microbiome research samples should be treated with the same privacy considerations as human tissues samples. We also suggest that returning individual microbiome-related findings could provide a powerful clinical tool for care management, but highlight the need for a more grounded understanding of contextual factors that may be unique to human microbiome research.Conclusions: We revisit the ELSI of biobanking and consider the impact that human microbiome research might have. Our discussion focuses on identifiability of human microbiome research samples, and return of research results and incidental findings for clinical management. [ABSTRACT FROM AUTHOR]

Rapid advances in human microbiome research point to an increasing range of health outcomes related to the composition of an individual's microbiome. To date, much research has focused on individual health, with a paucity of attention to public health implications. This is a critical oversight owing to the potentially shared nature of the human microbiome across communities and vertical and horizontal mechanisms for transferring microbiomes among humans. We explored some key ethical and social implications of human microbiome research for public health. We focused on (1) insights from microbiome research about damage to individual and shared microbiomes from prevalent societal practices, and (2) ethical and social implications of novel technologies developed on the basis of emerging microbiome science. [ABSTRACT FROM AUTHOR]

The article discusses ethical and social issues related to fecal microbiota transplantation (FMT) and other human microbial therapies. Topics discussed include use of FMT in conditions like clostridium difficile infections (CDI) and inflammatory bowel disease (IBD); biologic drugs require risk–benefit assessment not required of manufactured drugs to ensure quality and safety; and information on social acceptability of FMT.

The author discusses the impact of the changes in humam lifestyle to human microbiome. Topics discussed by the author include the influence of the overexploitation of human to a public resource to the composition of human microbiome, the changes in disease incidence in urbanized Western countries, and the opportunities provided by supporting microbiome conservation and stewardship.